ERBB2 and breast carcinoma: In a phase 3 trial for patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy, T-Dxd has been shown to yield a survival benefit in patients with HER2-low advanced breast cancer compared to the physician’s choice of chemotherapy [44].